Suppr超能文献

对睾丸生殖细胞肿瘤根治性睾丸切除术标本进行二次复查时病理报告存在差异。

Discrepancy in pathology reports upon second review of radical orchiectomy specimens for testicular germ cell tumors.

作者信息

Nason Gregory J, Sweet Joan, Landoni Lauren, Leao Ricardo, Anson-Cartwright Lynn, Mok Spencer, Guzylak Vanessa, D'Angelo Andrea, Fang Zhi Yi, Geist Ilana, Warde Padraig, Jewett Michael A S, Hamilton Robert J

机构信息

Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, ON, Canada.

Department of Pathology and Lab Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.

出版信息

Can Urol Assoc J. 2020 Dec;14(12):411-415. doi: 10.5489/cuaj.6481.

Abstract

INTRODUCTION

We sought to evaluate the discrepancies between primary pathology report and second pathology review of radical orchiectomy (RO) specimens.

METHODS

A retrospective review was performed of RO specimens from the Ontario Cancer Registry. All cases required both a primary pathology report and a second pathology review from another institution. Histopathological variables assessed included histological subtype and components of mixed germ cell tumor (GCT), pathological tumor (pT) stage, lymphovascular invasion (LVI), spermatic cord invasion, and surgical margin.

RESULTS

Between 1994 and 2015, 5048 ROs were performed with 2719 (53.9%) seminoma and 2029 (40.2%) non-seminoma. Of these, 519 (10.3%) received a second pathology review. There was concordance between primary pathology report and second pathology review in 326 (62.8%) cases. The most common discrepancies involved a change in pT stage (n=148, 28.5%), with upstaging in 83 (16%) and downstaging in 65 (12.5%) cases relative to the original pT stage. The second most common discrepancy regarded the reporting of LVI (n=121, 23.3%), with 62 (11.9%) reporting presence of LVI when the primary pathology report did not. Other discrepancies included a change in the histological subtype in 28 (5.4%) cases and spermatic cord margin status in five (9.6%) cases.

CONCLUSIONS

Only 10% of orchiectomy specimens underwent a second pathology review, with nearly 40% of reviews leading to a meaningful change in parameters. Such variation could lead to incorrect tumor staging, estimate of relapse risk, and inappropriate treatment decisions. Expert pathology review of RO specimens should be considered, as it has significant implications for decision-making.

摘要

引言

我们试图评估根治性睾丸切除术(RO)标本的初次病理报告与二次病理复查之间的差异。

方法

对安大略癌症登记处的RO标本进行回顾性研究。所有病例均需要初次病理报告以及来自另一家机构的二次病理复查。评估的组织病理学变量包括组织学亚型和混合性生殖细胞肿瘤(GCT)的成分、病理肿瘤(pT)分期、淋巴管浸润(LVI)、精索浸润和手术切缘。

结果

1994年至2015年间,共进行了5048例RO手术,其中精原细胞瘤2719例(53.9%),非精原细胞瘤2029例(40.2%)。其中,519例(10.3%)接受了二次病理复查。326例(62.8%)病例的初次病理报告与二次病理复查结果一致。最常见的差异涉及pT分期的改变(n = 148,28.5%),相对于原始pT分期,83例(16%)病例分期上调,65例(12.5%)病例分期下调。第二常见的差异是LVI的报告(n = 121,23.3%),62例(11.9%)病例在初次病理报告未提及LVI时报告存在LVI。其他差异包括28例(5.4%)病例的组织学亚型改变和5例(9.6%)病例的精索切缘状态改变。

结论

仅10%的睾丸切除标本接受了二次病理复查,近40%的复查导致参数有意义的改变。这种差异可能导致肿瘤分期错误、复发风险估计错误以及不适当的治疗决策。应考虑对RO标本进行专家病理复查,因为这对决策有重大影响。

相似文献

本文引用的文献

3
Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline.早期睾丸癌的诊断与治疗:AUA 指南。
J Urol. 2019 Aug;202(2):272-281. doi: 10.1097/JU.0000000000000318. Epub 2019 Jul 8.
5
Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer.睾丸癌生物标志物:精准医学在睾丸癌中的作用。
Clin Genitourin Cancer. 2019 Feb;17(1):e176-e183. doi: 10.1016/j.clgc.2018.10.007. Epub 2018 Oct 23.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验